Simple Summary Mutational hotspots have gained importance as oncological biomarkers in
recent years because of their potential as predictors of clinical outcomes and/or therapeutic …

The vast majority of pituitary neuroendocrine tumors (PitNETs) are benign and slow growing
with a low relapse rate over many years after surgical resection. However, about 40% are …

Context CHEK2 is a cell cycle checkpoint regulator gene with a long-established role as a
clinically relevant, moderate risk breast cancer predisposition gene, with greater risk …

Abstract Context and Objective The genetic profile of prolactinomas remains poorly
understood. Our objective is to identify somatic genetic alterations associated with …

The recent Consensus Statement on the diagnosis and management of prolactin-secreting
pituitary adenomas (prolactinomas) drew attention to molecular pathogenetic mechanisms …

Pituitary adenoma/pituitary neuroendocrine tumors (PitNETs) are the second most common
primary intracranial tumor and the most frequent neuroendocrine tumors/neoplasms of the …

Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and
approximately one-fifth of them are diagnosed in males. The clinical presentation of …

Simple Summary Pituitary neuroendocrine tumors (PitNETs) develop from anterior pituitary
cells and, although generally benign, comprise a small subset of therapy-resistant …

Durch die Zunahme der bildgebenden Untersuchungen nimmt auch die Diagnosehäufigkeit
hypophysärer Raumforderungen (Hypophyseninzidentalome) zu. Ein Großteil der …

Remissversion nationellt vårdprogram för hypofystumörer Page 1 Regionala cancercentrum
i samverkan Sveriges Kommuner och Regioner | 118 82 Stockholm Besök: Hornsgatan 20 …